Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China
A growing economy,large population base, and innovation-friendly environment are other keyparameters that are anticipated to drive the growth of the pharmaceuticalcontract manufacturing market in China. Further, in order to meet the growingdemand for their services, CMOs having manufacturing facilities in China areactively expanding their existing capacities and capabilities in the region.
To order this 200+page report, which features 85+ figures and 100+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html
The USD 13 billion(by 2030) financial opportunity within the pharmaceuticals contractmanufacturing market in China has been analyzed across the following segments:
§ Key GeographicalRegions
- Eastern China
- Southern China
- Northern China
§ Type of Product
- Active Pharmaceutical Ingredients (APIs)
- Drug Products
§ Type of Drug Product
- Solid
- Liquid / Semi-Solid
- Injectable
- Others
§ Scale of Operation
- Clinical
- Commercial
§ Company Size
- Small
- Mid-Sized
- Large / Very Large
The ChinaPharmaceutical Contract Manufacturing Services Market, 2020-2030. report features the following companies, which weidentified to be key players in this domain:
§ 2Y-Chem
§ AuriscoPharmaceutical
§ ChemPartner
§ Dorrapharma
§ Hubei BiocausePharmaceutical
§ Infoark
§ Ningbo MenovoPharmaceutical
§ ShandongXinhua Pharmaceutical
§ Shanghai AcebrightPharmaceuticals
§ STA Pharmaceutical
§ Zhejiang HuahaiPharmaceutical
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Case Study: Comparison of SmallMolecules and Large Molecules
5. Market Overview
6. Manufacturing Facilities of Pharmaceutical CMOsin China
7. Pharmaceutical Manufacturing Regulations inChina
8. Company Profiles
9. Big Pharma Initiatives in China
10. Recent Trends
11. Capacity Analysis
12. SWOT Analysis
13. Market Forecast
14. Case Study: Impact of Coronavirus Outbreak
14. Conclusion
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies andOrganizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
